HC Wainwright Issues Pessimistic Outlook for ORIC Earnings

Key Points

• HC Wainwright lowered its ORIC earnings forecasts, projecting a Q3 2026 loss of $0.40 per share versus $0.36 previously and a FY2026 loss of $1.54 per share.
• Despite the more pessimistic estimates, HC Wainwright maintained a Buy rating and $27 price target; analysts overall rate the stock “Moderate Buy,” with an average target of $19.45.
• Oric recently reported a quarterly loss of $0.38 per share, missing consensus by $0.02, while the stock traded near $13.73 and institutional investors owned approximately 95% of outstanding shares.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - HC Wainwright lowered their Q3 2026 EPS estimates for Oric Pharmaceuticals in a report issued on Monday, August 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.40) per share for the quarter, down from their previous forecast of ($0.36). HC Wainwright currently has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals' current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals' Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.54) EPS, Q3 2027 earnings at ($0.47) EPS and Q4 2027 earnings at ($0.49) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02).

ORIC has been the topic of a number of other research reports. Stifel Nicolaus assumed coverage on Oric Pharmaceuticals in a report on Friday, June 12th. They set a "buy" rating and a $14.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Benchmark reissued a "buy" rating on shares of Oric Pharmaceuticals in a research note on Monday, June 8th. Citigroup decreased their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a "buy" rating for the company in a report on Tuesday, May 5th. Finally, The Goldman Sachs Group raised Oric Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $15.00 price target for the company in a research note on Friday, May 15th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $19.45.

Oric Pharmaceuticals Trading Up 0.8%

ORIC stock opened at $13.73 on Wednesday. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -10.17 and a beta of 1.02. The firm's 50-day moving average price is $10.36 and its two-hundred day moving average price is $10.48. Oric Pharmaceuticals has a 12-month low of $7.23 and a 12-month high of $14.93.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Defilade Capital Management L.P. purchased a new stake in Oric Pharmaceuticals in the first quarter worth $10,680,000. Siren L.L.C. lifted its position in Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock valued at $37,987,000 after buying an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Oric Pharmaceuticals by 19.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company's stock worth $18,637,000 after buying an additional 244,060 shares during the period. UBS Group AG grew its position in shares of Oric Pharmaceuticals by 116.6% in the 4th quarter. UBS Group AG now owns 734,858 shares of the company's stock worth $6,011,000 after buying an additional 395,622 shares during the period. Finally, Candriam S.C.A. bought a new position in shares of Oric Pharmaceuticals in the 1st quarter worth about $7,274,000. Institutional investors own 95.05% of the company's stock.

More Oric Pharmaceuticals News

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $27 target price for Oric Pharmaceuticals (ORIC), providing a favorable valuation signal for investors. HC Wainwright analyst estimates and rating
• Neutral Sentiment: HC Wainwright projected continued quarterly losses, including EPS of $(0.43) in Q1 2027, $(0.45) in Q2 2027, $(0.47) in Q3 2027 and $(0.49) in Q4 2027, implying a full-year 2027 loss of $(1.85). The estimates reflect continued research and development spending rather than near-term profitability. Oric Pharmaceuticals 2027 EPS estimates
• Negative Sentiment: HC Wainwright reduced its forecasts for Q3 2026 EPS to $(0.40) from $(0.36), Q4 2026 EPS to $(0.42) from $(0.37), and FY2026 EPS to $(1.54) from $(1.41). These revisions point to somewhat higher expected losses and may limit near-term upside, although the estimates remain close to the broader full-year consensus of $(1.51). Oric Pharmaceuticals 2026 EPS estimate revisions
• Neutral Sentiment: Reported short interest was listed at zero shares with zero days to cover, but the data appears inconsistent and offers little actionable information about trading pressure.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source